v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Expenses            
Research and development $ 7,187,235   $ 1,298,041   $ 12,442,201 $ 2,660,479
General and administrative 3,454,924   2,076,108   14,871,510 4,616,554
Total expenses 10,642,159   3,374,149   27,313,711 7,277,033
Loss from operations (10,642,159)   (3,374,149)   (27,313,711) (7,277,033)
Foreign exchange losses (14,351)   (21,110)   (16,155) (29,486)
Investment income 569,591   136,671   1,199,193 294,959
Changes in fair value of the warrant liability 27,553,204       (81,807,426)  
Net income (loss) 17,466,285 $ (125,404,384) (3,258,588) $ (3,752,972) (107,938,099) (7,011,560)
Undistributed earnings attributable to participating preferred stock (819,327)          
Net income (loss) attributable to common stockholders $ 16,646,958   $ (3,258,588)   $ (107,938,099) $ (7,011,560)
Net income (loss) per share, basic $ 0.36   $ (0.43)   $ (2.38) $ (0.93)
Weighted average shares outstanding,basic 46,599,044   7,568,981   45,257,190 7,568,981
Net income (loss) per share, diluted $ (0.14)   $ (0.43)   $ (2.38) $ (0.93)
Weighted average shares outstanding, diluted 79,104,585   7,568,981   45,257,190 7,568,981